Skip to content

Study · Non-randomized trial · n = 40 · 2026

2 results

[Neurocognitive characteristics in children with sluggish cognitive tempo].

Chutko LS, Yakovenko EA, Surushkina SY, Shcheglova LV

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2026

PMID42899917 (opens in a new tab)DOI10.17116/jnevro202612609152 (opens in a new tab)PepBankPUB-42899917
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with sluggish cognitive tempo, improvement across attention, working memory, fatigue and reading domains occurred in 82% after Cortexin treatment.

    In plain wordsIn children with sluggish cognitive tempo, 82% improved across listed cognitive and symptom domains after Cortexin treatment compared with pretreatment.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseMultidomain cognitive and symptom improvement
    Study

    n = 40

    Comparator
    pretreatment
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 mg every other day · intramuscular · 10 injectionsAs given in this study (human).

    Measurements

    Proportion of cases improved
    82%
    cases at follow-up after Cortexin treatment

    Source sentences

    Summary
    A follow-up assessment after treatment revealed improvements in inattention, severity of working memory impairment, asthenic symptoms, and reading skills in 82% of cases.
    2 context sentences
    Summary · context
    The main study group included 40 children aged 12 to 14 years with symptoms consistent with SCT manifestations.
    Summary · context
    Cortexin was administered intramuscularly at a standard dosage of 10 mg every other day across 10 injections to patients diagnosed with SCT.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with sluggish cognitive tempo, frontal and central EEG alpha-band power decreased in both hemispheres after Cortexin treatment.

    In plain wordsIn children with sluggish cognitive tempo, frontal and central brain alpha-wave power decreased after Cortexin treatment compared with pretreatment.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseFrontal and central EEG alpha-band power
    Study

    n = 40

    Comparator
    pretreatment
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    10 mg every other day · intramuscular · 10 injectionsAs given in this study (human).

    Source sentences

    Summary
    Additionally, EEG analysis post-treatment indicated a reduction in alpha-band power in the frontal and central leads of both hemispheres, suggesting enhanced overall cortical activation.
    2 context sentences
    Summary · context
    The main study group included 40 children aged 12 to 14 years with symptoms consistent with SCT manifestations.
    Summary · context
    Cortexin was administered intramuscularly at a standard dosage of 10 mg every other day across 10 injections to patients diagnosed with SCT.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.